Achilles Therapeutics names ex-GSK exec at CBO
UK biotech start-up Achilles Therapeutics today announced the appointment of Beverley Carr as chief business officer, with effect from November 4, 2019.
Ms Carr brings over 20 years of business development experience in global pharma and biotechnology companies. Prior to joining Achilles, she was vice president, business development for the immuno-inflammation therapy area at GlaxoSmithKline (LSE: GSK) where she led more than 20 transactions encompassing discovery collaborations, new company creation, M&A and late-stage product partnering deals.
“We are delighted to welcome Beverley to our team as we progress our innovative therapies into the clinic. She brings a wealth of knowledge and expertise and is ideally suited to lead our strategic engagement with a select group of external partners,” said Achilles’ chief executive Iraj Ali.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze